Incyte Corporation (INCY)
NASDAQ · Healthcare · Biotechnology
Incyte Corporation is a Healthcare company with a market capitalization of $24.23B and a trailing P/E ratio of 15.2.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q2 2026 | July 28, 2026 | $2.80 | $1.76 | +59.1% |
| Q1 2026 | April 28, 2026 | $1.81 | $1.34 | +35.1% |
| Q4 2025 | February 10, 2026 | $1.80 | $1.92 | -6.3% |
| Q3 2025 | October 28, 2025 | $2.26 | $1.64 | +37.8% |
| Q2 2025 | July 29, 2025 | $1.57 | $1.47 | +6.8% |
| Q1 2025 | April 29, 2025 | $1.16 | $1.03 | +12.6% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 10,512,123 | 5.08% | 6.5 | -0.6% |
| June 30, 2026 | 10,579,770 | 5.12% | 4.8 | +0.2% |
| June 15, 2026 | 10,560,807 | 5.11% | 4.7 | -7.4% |
| May 29, 2026 | 11,402,307 | 5.51% | 9.2 | +3.3% |
| May 15, 2026 | 11,040,495 | 5.34% | 8.7 | -2.8% |
| April 30, 2026 | 11,358,353 | 5.49% | 7.1 | -5.2% |
| April 15, 2026 | 11,974,587 | 5.85% | 9.8 | +4.6% |
| March 31, 2026 | 11,444,784 | 5.59% | 6.6 | +3.6% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Incyte Corporation's market cap?
As of August 13, 2026, Incyte Corporation (INCY) has a market capitalization of $24.23B.
What is Incyte Corporation's P/E ratio?
Incyte Corporation trades at a trailing price-to-earnings (P/E) ratio of 15.2. Its forward P/E is 38.4.
Does Incyte Corporation pay a dividend?
Incyte Corporation does not currently pay a dividend.
What sector is INCY in?
Incyte Corporation is in the Healthcare sector, specifically the Biotechnology industry.
What is Incyte Corporation's short interest?
As of the July 15, 2026 FINRA settlement, 10,512,123 INCY shares were sold short, or 5.08% of shares outstanding. Days to cover: 6.5. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Incyte Corporation's revenue?
In its latest reported fiscal year (ending December 31, 2025), Incyte Corporation reported revenue of $5.14B and net income of $1.29B.
Ask your own questions about INCY
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.